Identification of the ligand of a human public anti-HCMV/cancer γδ T cell receptor

Deborah Gatti
Faculty of Pharmacy

Gamma delta (GT) T lymphocytes are peculiar in that they can fight infectious agents during the fetal stage of human development. The team led by David Vermijlen (department of pharmacotherapy and galenic pharmacy) has also found that some of these lymphocytes, which express the Vg8Vd1 receptor, also react to cancer cells.

These Vg8Vd1 GD T cells are present in all individuals, could therefore be of interest when studying the development of cancer immunotherapies. However, one of the conditions for this is to determine what stimulates these cells. This is the goal of the new Marie Skłodowska-Curie ‘GD TCR Ligand’ project, led by Deborah Gatti: finding the ligand for the Vg8Vd1 receptor, in order to better understand the role and functioning of GC lymphocytes and might trigger an anti-cancer reaction.

End of the project: 28/02/2019

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 751954
Created on August 6, 2018